Sussex research points to new effective breast cancer treatment


Five-year study, the structure-function relationship of oncogenic LMTK3, Science Advances, suggests that LMTK3 inhibitors could be effectively used for the treatment of breast cancer, and potentially other types of cancer


Credit: Courtesy of University of Sussex

An international study led by scientists at the University of Sussex has provided strong evidence for an effective new target for breast cancer treatment. The five-year study, called “The structure-function relationship of oncogenic LMTK3” to be published in Science Advances, involved researchers from seven institutions across three countries including the UK’s Diamond Light Source. It suggests that LMTK3 inhibitors could be effectively used for the treatment of breast cancer, and potentially other types of cancer. The structure of oncogenic LMTK3 (Lemur Tyrosine Kinase 3 ) determines its role and functions allowing drug inhibition as a new therapeutic strategy

It is hoped the research will allow the further development and optimisation of LMTK3 inhibitors as a new type of orally-administered anticancer drug for patients and have potential value not only for breast cancer patients but also for lung, stomach, thyroid and bladder cancer patients.

LMTK3 is a protein implicated in the development and progression of different malignancies and other diseases (eg. central nervous system related), which is not typically included in commercial kinase screening assays. The research successfully demonstrates that LMTK3 is an active kinase and reports a compound which binds to, and effectively inhibits, this protein resulting in anticancer effects in cells and in breast cancer models in mice.

Georgios Giamas, Professor of Cancer Cell Signalling at the University of Sussex, who led the research, says: “By solving the crystal structure of LMTK3, we have demonstrated that it possesses all of the hallmarks of an active protein kinase. LMTK3 plays a pivotal role in controlling cellular processes, and we have previously shown that active LMTK3 makes some cancer treatments (eg. chemotherapy and endocrine therapies) less effective.”

“We are now in the process of taking this research to the next stage by developing LMTK3 specific drugs. We hope that in the next five years we will be undertaking clinical trials, which is incredibly quick for this type of process.”

It is expected that the development of oral LMTK3 inhibitors may have the potential for broad clinical utility, either as a monotherapy, or as a combinational therapy, for example combined with chemotherapy, immunotherapy or endocrine treatments. Consequently, an LMTK3 inhibitor could be used alongside complementary therapies to increase the therapeutic efficacy and help overcome mechanisms of resistance to existing cancer therapies.

The researchers say that the work is a great example of international science collaboration with several groups coming together to help with a challenging project. In particular the OPPF (Oxford Protein Production Facility) and the UK’s synchrotron, Diamond Light Source worked with the groups to produce their protein of interest (LMTK3) and to help solve its crystal structure. “It is often difficult to obtain large well diffracting crystals and LMTK3 was no exception. Through close collaboration between the OPPF and I24 and exploiting the microfocused X-ray beam at I24 to collect wedges of data from multiple crystals we were able to obtain diffraction data key to the study,” commented Robin Owen, Principal Beamline Scientist of MX beamline I24 at Diamond. This research project is also a great demonstration of the powerful synergy between Diamond and its neighbouring research institutes like the Research Complex at Harwell which housed sample preparation.


The paper: The structure-function relationship of oncogenic LMTK3 will be published in the journal Science Advances. 13 November 2020 – DOI: 10.1126/sciadv.abc3099.

Authors: A. Ditsiou; C. Cilibrasi; L. Milton-Harris; V. Vella; T. Gagliano; M.C. Iachini; T. Simon; C. Prodromou; G. Giamas; University of Sussex N. Simigdala; P. Ntavelou; A. Klinakis

Biomedical Research Foundation of the Academy of Athens A. Papakyriakou National Centre for Scientific Research “Demokritos” J.E. Nettleship; R.J. Owens University of Oxford J.E. Nettleship; R.J. Owens Research Complex at Harwell; J.H. Lo; S. Soni; G. Smbatyan; H.-J. Lenz University of Southern California; S. Khurshid; P. Carter; N.E. Chayen; J. Stebbing Imperial College; L. Zhou; S. Hassell-Hart; L.H. Pearl; S.M. Roe; J. Spencer University of Sussex; R.L. Owen – Diamond Light Source; R.J. Owens – The Rosalind Franklin Institute; T. Gagliano – University of Udine

For further media information: please contact Diamond Communications: Lorna Campbell +44 7836 625999 or Isabelle Boscaro-Clarke +44 1235 778130

About Diamond Light Source:

Diamond Light Source is the UK’s national synchrotron, providing industrial and academic user communities with access to state-of-the-art analytical tools to enable world-changing science. Shaped like a huge ring, it works like a giant microscope, accelerating electrons to near light speeds, to produce a light 10 billion times brighter than the Sun, which is then directed off into 33 laboratories known as ‘beamlines’. In addition to these, Diamond offer access to several integrated laboratories including the Electron Bio-imaging Centre (eBIC) and the Electron Physical Science Imaging Centre (ePSIC).

Diamond serves as an agent of change, addressing 21st century challenges such as disease, clean energy, food security and more. Since operations started, more than 14,000 researchers from both academia and industry have used Diamond to conduct experiments, with the support of approximately 700 world-class staff. More than 9,000 scientific articles have been published by our users and scientists.

Funded by the UK Government through the Science and Technology Facilities Council (STFC), and by the Wellcome Trust, Diamond is one of the most advanced scientific facilities in the world, and its pioneering capabilities are helping to keep the UK at the forefront of scientific research.

Media Contact
Lorna Campbell, Diamond Light Source
[email protected]

Related Journal Article

Leave A Reply

Your email address will not be published.